Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease.
Sawamoto N, Doi D, Nakanishi E, Sawamura M, Kikuchi T, Yamakado H, Taruno Y, Shima A, Fushimi Y, Okada T, Kikuchi T, Morizane A, Hiramatsu S, Anazawa T, Shindo T, Ueno K, Morita S, Arakawa Y, Nakamoto Y, Miyamoto S, Takahashi R, Takahashi J.
Sawamoto N, et al. Among authors: hiramatsu s.
Nature. 2025 May;641(8064):971-977. doi: 10.1038/s41586-025-08700-0. Epub 2025 Apr 16.
Nature. 2025.
PMID: 40240591
Free PMC article.
Clinical Trial.